AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have presented new, long-term follow-up results for Calquence (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma and updated results of an ongoing clinical trial assessing acalabrutinib monotherapy in treatment-naïve patients with chronic lymphocytic leukemia at ASH.
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
